Evidence map›Paper›PMID 37072150›Full record

ArticleBMJ (Clinical research ed.)2023

Denosumab and incidence of type 2 diabetes among adults with osteoporosis: population based cohort study.

Houchen Lyu, Sizheng Steven Zhao, Licheng Zhang, Jie Wei, Xiaoxiao Li, Hui Li, Yi Liu, Pengbin Yin, Vibeke Norvang, Kazuki Yoshida and 5 more

Open access · hybridAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ (Clinical research ed.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
12.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Bone as an endocrine regulator of lipid and energy metabolism.Reviews in endocrine & metabolic disorders · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. The role of bone in whole-body energy metabolism.Nature reviews. Endocrinology · 2025
    Review
  13. Article
  14. Review
  15. Observational
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 4 countries.

Houchen LyuDepartment of Orthopaedics, The Chinese PLA General Hospital, Beijing 100853, China.
Sizheng Steven ZhaoCentre for Epidemiology Versus Arthritis, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.
Licheng ZhangDepartment of Orthopaedics, The Chinese PLA General Hospital, Beijing 100853, China.
Jie WeiDepartment of epidemiology and health statistics, Xiangya School of Public Health, Central South University, Changsha, China.
Xiaoxiao LiDepartment of Orthopaedics, Xiangya Hospital, Central South University, Changsha 410008, China.
Hui LiDepartment of Orthopaedics, Xiangya Hospital, Central South University, Changsha 410008, China.
Yi LiuDivision of Endocrinology, New York Presbyterian Hospital, Weill Cornell Medical College, New York, NY, USA.
Pengbin YinDepartment of Orthopaedics, The Chinese PLA General Hospital, Beijing 100853, China.
Vibeke NorvangDivision of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.
Kazuki YoshidaDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA 02115, USA.
Sara K TedeschiDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA 02115, USA.
Chao ZengDepartment of Orthopaedics, Xiangya Hospital, Central South University, Changsha 410008, China.
Guanghua LeiDepartment of Orthopaedics, Xiangya Hospital, Central South University, Changsha 410008, China lei_guanghua@csu.edu.cn pftang301@126.com dsolomon@bwh.harvard.edu.ORCID 0000-0003-2987-138X
Peifu TangDepartment of Orthopaedics, The Chinese PLA General Hospital, Beijing 100853, China lei_guanghua@csu.edu.cn pftang301@126.com dsolomon@bwh.harvard.edu.ORCID 0000-0003-4279-1704
Daniel H SolomonDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA 02115, USA lei_guanghua@csu.edu.cn pftang301@126.com dsolomon@bwh.harvard.edu.ORCID 0000-0001-8202-5428
Central South University · CNBrigham and Women's Hospital · USChinese PLA General Hospital · CNDiakonhjemmet Hospital · NONewYork–Presbyterian Hospital · USUniversity of Manchester · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo estimate the effect of denosumab compared with oral bisphosphonates on reducing the risk of type 2 diabetes in adults with osteoporosis.

designPopulation based study involving emulation of a randomized target trial using electronic health records.

settingIQVIA Medical Research Data primary care database in the United Kingdom, 1995-2021.

participantsAdults aged 45 years or older who used denosumab or an oral bisphosphonate for osteoporosis.

main outcome measuresThe primary outcome was incident type 2 diabetes, as defined by diagnostic codes. Cox proportional hazards models were used to estimate adjusted hazard ratios and 95% confidence intervals, comparing denosumab with oral bisphosphonates using an as treated approach.

results4301 new users of denosumab were matched on propensity score to 21 038 users of an oral bisphosphonate and followed for a mean of 2.2 years. The incidence rate of type 2 diabetes in denosumab users was 5.7 (95% confidence interval 4.3 to 7.3) per 1000 person years and in oral bisphosphonate users was 8.3 (7.4 to 9.2) per 1000 person years. Initiation of denosumab was associated with a reduced risk of type 2 diabetes (hazard ratio 0.68, 95% confidence interval 0.52 to 0.89). Participants with prediabetes appeared to benefit more from denosumab compared with an oral bisphosphonate (hazard ratio 0.54, 0.35 to 0.82), as did those with a body mass index ≥30 (0.65, 0.40 to 1.06).

conclusionsIn this population based study, denosumab use was associated with a lower risk of incident type 2 diabetes compared with oral bisphosphonate use in adults with osteoporosis. This study provides evidence at a population level that denosumab may have added benefits for glucose metabolism compared with oral bisphosphonates.

Indexed as

Bone Density Conservation AgentsDiabetes Mellitus, Type 2OsteoporosisAgedAged, 80 and overCohort StudiesDenosumabDiphosphonatesFemaleHumansIncidenceMaleMiddle AgedBone Density Conservation AgentsDenosumabDiphosphonates

Identifiers

PMID37072150
PMCPMC10111187
OpenAlexW4366303835

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.